A new fetal RHD genotyping test: Costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales
2011

Cost-Effectiveness of a New Fetal RHD Genotyping Test

publication Evidence: low

Author Information

Author(s): Szczepura Ala, Osipenko Leeza, Freeman Karoline

Primary Institution: Warwick Medical School, University of Warwick, Coventry, UK

Hypothesis

Is non-invasive prenatal diagnosis (NIPD) cost-effective for targeting anti-D prophylaxis in RhD negative pregnancies?

Conclusion

NIPD testing for targeting anti-D prophylaxis is currently not cost-effective for large-scale implementation in England and Wales.

Supporting Evidence

  • NIPD testing could lead to increased maternal sensitizations if not implemented carefully.
  • Current anti-D prophylaxis policies are already effective in reducing sensitization rates.
  • Cost savings from NIPD testing are minimal compared to the potential risks involved.

Takeaway

This study looked at a new test to see if it could save money when giving treatment to pregnant women. It found that the test might not be worth it because it could lead to more problems instead of saving money.

Methodology

An economic analysis comparing two scenarios of NIPD implementation against current policies.

Potential Biases

Potential bias due to reliance on existing data and assumptions about test performance and costs.

Limitations

The study's conclusions are limited by uncertainties regarding the royalty fees for NIPD tests and the reliability of NIPD in diverse populations.

Participant Demographics

Approximately 10% of pregnancies involve RhD negative mothers, with varying rates in different ethnic groups.

Digital Object Identifier (DOI)

10.1186/1471-2393-11-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication